ICLUSIG Drug Patent Profile

When do Iclusig patents expire, and what generic alternatives are available?

Iclusig is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and nine patent family members in twenty-four countries.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ponatinib hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Iclusig

Iclusig was eligible for patent challenges on December 14, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 19, 2031. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (ponatinib hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for ICLUSIG

International Patents:	109
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	50
Clinical Trials:	26
Patent Applications:	1,058
Drug Prices:	Drug price information for ICLUSIG
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ICLUSIG
What excipients (inactive ingredients) are in ICLUSIG?	ICLUSIG excipients list
DailyMed Link:	ICLUSIG at DailyMed

See drug prices for ICLUSIG

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ICLUSIG

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)

NDA:

203469

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ICLUSIG

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assistance Publique - Hpitaux de Paris	PHASE2
University of Chicago	Phase 2
Institute of Hematology and Blood Transfusion, Czech Republic	Phase 2

See all ICLUSIG clinical trials

Pharmacology for ICLUSIG

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Paragraph IV (Patent) Challenges for ICLUSIG

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ICLUSIG	Tablets	ponatinib hydrochloride	10 mg and 30 mg	203469	1	2022-12-12
ICLUSIG	Tablets	ponatinib hydrochloride	15 mg and 45 mg	203469	1	2021-03-31

US Patents and Regulatory Information for ICLUSIG

ICLUSIG is protected by seventeen US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-003	Apr 23, 2015		RX	Yes	No	9,493,470		Y	Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-003	Apr 23, 2015		RX	Yes	No	11,192,897			Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-002	Dec 14, 2012		RX	Yes	No	9,493,470		Y	Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-003	Apr 23, 2015		RX	Yes	No	8,114,874		Y	Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-001	Dec 14, 2012		RX	Yes	No	11,192,895

International Patents for ICLUSIG

When does loss-of-exclusivity occur for ICLUSIG?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

France

Hungary

Israel

Japan

Luxembourg

Mexico

Poland

Portugal

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ICLUSIG around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013204506
Australia	2016210725
Australia	2018201013
Australia	2019240721
Australia	2021221493

Supplementary Protection Certificates for ICLUSIG

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1973545	C300631	Netherlands		PRODUCT NAME: PONATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, SOLVAAT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
1973545	CA 2013 00066	Denmark		PRODUCT NAME: POATINIB, HERUNDER PONATINIB HYDROCHLORID; REG. NO/DATE: EU/1/13/839/001-004 20130701
1973545	PA2013027	Lithuania		PRODUCT NAME: PONATINIBUM; REGISTRATION NO/DATE: EU/1/13/839/001, 2013 07 01 EU/1/13/839/002, 2013 07 01 EU/1/13/839/003, 2013 07 01 EU/1/13/839/004 20130701
1973545	92327	Luxembourg		PRODUCT NAME: PONATINIB SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE
1973545	13C0069	France		PRODUCT NAME: PONATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, SOLVATE OU HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701

ICLUSIG (ponatinib) market dynamics and financial trajectory through exclusivity, pricing, and competitive displacement

Last updated: July 22, 2026

Executive summary: ICLUSIG (ponatinib) remains a high-value, low-volume oncology asset with a narrow label and strict safety-driven use patterns. Revenue has been shaped less by broad demand and more by (1) progressive restriction of use after safety communications and label tightening, (2) payer and site-of-care access controls tied to monitoring requirements, and (3) displacement pressure from kinase and non-kinase alternatives in chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). Financial trajectory shows a move from high-peak expectations into a steadier, smaller commercial base post-restriction, with ongoing offset effects from later-line adoption and continuing high pricing (subject to net pricing adjustments). Patent-driven generic pressure is limited in the US by ongoing patent/Orange Book coverage duration, and in the near term by the difficulty of carving out a workable non-infringing ponatinib launch. Competitive headwinds from next-generation BCR::ABL1 TKIs and positioning of therapies by mutation status and prior TKI exposure continue to cap upside.

ICLUSIG (ponatinib) market dynamics: who buys it and how is it used?

Featured snippet answer: ICLUSIG is purchased primarily by oncology and hematology centers treating patients with resistant or intolerant CML or Ph+ ALL, with prescribing concentrated in later-line and mutation-selected scenarios due to safety constraints and required monitoring.

What patient segments drive ICLUSIG demand?

ICLUSIG is a BCR::ABL1 tyrosine kinase inhibitor with activity against multiple BCR::ABL1 mutations associated with resistance to earlier TKIs. Commercial demand is segmented by disease stage and line of therapy:

• CML (chronic, accelerated, or blast phases) after resistance or intolerance to prior therapies.
• Ph+ ALL after resistance or intolerance to prior therapies.
• Mutation-selected use where prior TKI failure is linked to specific BCR::ABL1 resistance profiles.

Demand is further filtered by safety-limited eligibility, including cardiovascular risk screening and thromboembolic risk management, which reduces eligible volume relative to a typical “unrestricted” oral TKI.

How label restrictions changed commercial behavior

After safety updates, the label and prescribing standards tightened around thrombotic and vascular risk. This changed market dynamics in three ways:

1. Lower addressable population: clinicians shifted away from earlier-line “coverage filling” and used ICLUSIG only when benefits outweigh risk.
2. More structured access: payers and centers increased prior-authorization scrutiny and documentation requirements tied to monitoring and prior TKI exposure.
3. Dose and interruption practices: real-world prescribing patterns moved toward more cautious dosing, dose modifications, and discontinuations, affecting treatment continuity and lifetime patient value.

What is the competitive market map?

ICLUSIG competes in CML and Ph+ ALL TKI-driven treatment landscapes. Key dynamic is that younger TKIs and other agents can cover larger patient pools where clinicians have flexibility on sequence, leaving ponatinib to a smaller residual segment.

Competitive forces include:

• Earlier-generation and next-generation BCR::ABL1 TKIs used based on line, tolerability, mutation profile, and guideline alignment.
• Treatment selection based on mutation status: clinicians often pick agents with documented activity for a given resistance pattern, pushing ponatinib toward specific mutation- and resistance-defined niches.
• Combination strategies and alternative pathways in later lines, which reduces the “must-use” status of any single TKI in heavily pretreated settings.

How has ICLUSIG’s revenue trajectory evolved as restrictions and competition tightened?

Featured snippet answer: ICLUSIG’s financial trajectory tracks a pattern common to high-cost, safety-constrained oncology drugs: an initial growth phase followed by revenue stabilization at a smaller base after label tightening, with subsequent modest swings driven by line-of-therapy adoption and ongoing net price dynamics.

Typical revenue drivers for a safety-restricted specialty oncology TKI

For drugs like ICLUSIG, revenue is driven by:

• Patient starts (new eligible cases meeting restricted criteria)
• Treatment duration (interruptions, discontinuations, dose modifications)
• Dose intensity economics (net pricing varies with rebates and dose utilization)
• Net price vs list price (payer contracting and HUB dynamics)
• Geographic and center concentration (regional adoption lags and site protocols)

What financial profile fits ponatinib

ICLUSIG is priced at a high specialty oncology level and sold as an oral branded medicine. The commercial profile tends to show:

• High gross margin early due to brand exclusivity.
• Net revenue pressure through contracting and rebate evolution as competition intensifies and payers demand tighter utilization controls.
• Limited “volume expansion” because label restrictions and safety monitoring narrow the eligible population.

What magnitude matters most: starts vs continuity

In constrained therapies, the key variable is not only whether patients are prescribed, but whether they remain on therapy. For ponatinib, real-world safety management can reduce duration, which dampens revenue even when prescribing continues in a stable number of patients.

When does ICLUSIG lose exclusivity in the US and what does that mean for generic entry?

Featured snippet answer: US market exclusivity risk for ICLUSIG depends on the interaction of Orange Book drug substance and formulation patents with any regulatory exclusivity and the timeline for patent expirations. For a small-molecule oral drug, generics can be blocked by unexpired method-of-use and formulation patents even after some drug product patents expire, limiting “easy” Paragraph IV strategies.

How exclusivity usually works for ICLUSIG-like small molecules

For small-molecule kinase inhibitors, generic entry can be blocked by:

• Drug substance patents (composition of matter)
• Formulation patents (specific dosage forms, coatings, release, stability)
• Method-of-use patents tied to specific patient populations, dosing strategies, or treatment regimens

Even if a generic can clear one type of patent, it still faces a “patent thicket” that can delay launch until the last relevant listed patent expires or is cleared via settlements.

Patent-driven entry scenarios

For ICLUSIG, the market implication of exclusivity loss is straightforward:

• If composition-of-matter coverage ends first, generics can still be delayed by formulation or method-of-use claims.
• If method-of-use patents remain, a generic may face labeling carve-outs or litigation that prevents full label parity.
• If generic launch is delayed by settlements, the revenue impact shifts from “hard stop” to “gradual erosion” when authorized generics or non-exclusive launches begin.

What patents protect ICLUSIG (ponatinib) and how strong is the patent estate?

Featured snippet answer: ICLUSIG’s US patent estate typically includes multiple layers covering composition of matter, formulations, and dosing or therapeutic use. Strength is assessed by how many listed patents remain unexpired and by the breadth of claims that cover non-infringing design-around options.

Which patent categories matter most for market exclusion?

For market timing and generic risk, prioritize:

• Composition-of-matter: sets the “earliest plausible” expiry baseline.
• Formulation: blocks manufacturing or dosage-form workarounds.
• Method-of-use: can block label-aligned generic entry or force carve-outs.

How to estimate market impact from the patent stack

A high-impact patent estate usually means:

• Multiple Orange Book listings tied to the same NDA product
• Later-expiring formulation and method-of-use patents
• Litigation or settlement activity that extends practical barriers

What is the Orange Book status of ICLUSIG?

Featured snippet answer: ICLUSIG’s Orange Book status is defined by the set of listed patents for the NDA and each patent’s expiration and exclusivity codes. This listing drives real-world generic entry timelines because Paragraph IV challenges attach to specific patents.

Why Orange Book codes and patent expiry dates determine launch timing

Even if a composition-of-matter patent expires, remaining formulation or method-of-use patents can still:

• trigger a new litigation wave
• force labeling carve-outs
• delay full commercialization of generics

Has ICLUSIG faced Paragraph IV challenges or patent litigation?

Featured snippet answer: ICLUSIG has been subject to the patent-litigation pattern common to branded specialty oncology drugs, where generic filers target Orange Book-listed patents with Paragraph IV certifications and litigation or settlements follow.

How litigation affects commercial trajectory

Litigation changes revenue trajectory through:

• Delayed generic entry: settlements can keep exclusivity intact beyond original expiry.
• Authorized generic timing: if an authorized generic is launched during or after exclusivity, revenue can drop faster even without a “hard” infringement decision.
• Label carve-out impacts: if a generic launches with a narrowed label, it can reduce substitution and maintain brand share.

What formulation and dosing patents matter for manufacturing and design-around?

Featured snippet answer: For oral small-molecule TKIs, formulation and dosing patents matter because they define what constitutes a non-infringing product. A generic can avoid composition-of-matter issues but still need to clear dosage-form and method-of-use claims to match brand prescribing.

Dosage-form patent themes for oral TKIs

Typical claim areas include:

• Specific tablet/capsule composition
• Release characteristics (if applicable)
• Stability and manufacturing process constraints
• Methods of administering ponatinib for a defined therapeutic context

How does ICLUSIG compare with other BCR::ABL1 inhibitors on market adoption and displacement risk?

Featured snippet answer: ICLUSIG’s adoption is narrower than broadly used TKIs because safety management reduces eligible patient share and clinical positioning is more constrained to resistant or intolerant populations with relevant mutation or failure history.

Key displacement pathways

• Mutation-guided substitution: prescribers select the most appropriate agent based on resistance patterns.
• Sequence preference: earlier-line TKIs can absorb new diagnoses and earlier relapses, leaving ponatinib for later-line residual use.
• Safety profile comparison: payers and providers may reduce ponatinib share when other options offer comparable efficacy with less vascular risk burden.

Commercial implication

As competing agents deepen their guideline position and real-world share, ponatinib’s growth ceiling tightens. Revenue stays resilient only if:

• later-line incidence grows faster than competitors
• clinicians maintain ponatinib’s role in mutation-selected niches
• dosing adjustments support continued patient persistence

Regulatory and payer dynamics: what determines access to ICLUSIG?

Featured snippet answer: ICLUSIG access is driven by safety monitoring requirements, prior authorization criteria, and site-level protocol adherence tied to thromboembolic risk mitigation.

What payers focus on

• Prior TKI exposure documentation
• Mutation status documentation when required by payer policy
• Cardiovascular risk screening adherence
• Evidence of monitoring plans

Site-of-care and real-world prescribing

Because administration is oral, the site focus shifts to hematology/oncology practices that handle:

• risk screening
• longitudinal monitoring
• dose interruption workflows

These operational burdens reduce diffusion beyond specialty centers and keep growth concentrated.

Biosimilar risk: is ICLUSIG exposed like biologics?

Featured snippet answer: No biosimilar risk applies to ICLUSIG because ponatinib is a small molecule. Generic substitution is the relevant threat vector, not biosimilars.

Revenue exposure under generic entry: what happens when patents expire?

Featured snippet answer: When relevant Orange Book patents expire or are cleared, generic erosion can be swift for a widely prescribed oral drug, but for ICLUSIG it is typically moderated by label restriction, safety management protocols, and the continuing importance of center experience and payer authorization. The biggest revenue impact is usually tied to whether a generic can launch with label parity and without litigation that forces carve-outs.

Generic launch scenarios and expected market impact

• Full-label generic launch: faster erosion, margin compression, rapid switching.
• Carve-out label or restricted claims: slower switching, brand retention in niches where payers and clinicians require specific label alignment.
• Launch delayed by settlements: revenue declines later but with potentially abrupt step-down depending on whether an authorized generic arrives.

Key Takeaways

• ICLUSIG’s market is defined by a restricted, later-line and mutation-selected patient population shaped by safety communications and monitoring requirements.
• The financial trajectory is consistent with specialty oncology patterning: initial upside, followed by stabilization at a smaller eligible base as restrictions tighten and competing BCR::ABL1 inhibitors absorb broader share.
• Patent and Orange Book status govern the realistic timing of generic substitution; formulation and method-of-use patents can extend barriers even when some earlier coverage ends.
• Generic entry is the primary long-term risk vector; biosimilar risk does not apply to ponatinib.
• Revenue sensitivity is highest to patient starts and persistence, not just dosing levels, because safety management can shorten duration.

FAQs

1. What drives ICLUSIG prescribing rates in CML and Ph+ ALL after prior TKI failure?
   Mutation-relevant resistance, line of therapy, and safety-eligibility screening.

2. Which therapy substitutes most often for ponatinib in later-line CML?
   Next-generation and alternative BCR::ABL1 TKIs selected by mutation and prior exposure, plus non-TKI pathway options in selected settings.

3. What role do payer prior authorizations play in ICLUSIG net revenue outcomes?
   They determine eligible starts and treatment persistence by enforcing documentation and monitoring adherence.

4. How do method-of-use patents change generic launch feasibility for ICLUSIG?
   They can prevent label parity or force litigation and carve-outs even after composition-of-matter expiry.

5. Is an authorized generic likely to accelerate ICLUSIG revenue erosion post-expiry?
   If authorized, it can drive faster price competition once the brand’s practical exclusivity ends.

References

(Only cited sources.)

DrugChatter Q&A for ICLUSIG

Iclusig specialty pharmacy?
Iclusig mechanism of action?
Iclusig patient assistance program?
How much does iclusig cost?
What are the benefits of Iclusig?